IQVIA AI Solution Receives 2024 Frost & Sullivan Global Customer Value Leadership Award
September 19 2024 - 8:00AM
Business Wire
Award Recognizes Leadership in AI Regulatory
and Quality Solutions for Healthcare
IQVIA™ (NYSE:IQV), a leading global provider of advanced
analytics, technology solutions and clinical research services to
the life sciences industry, today announced that Frost &
Sullivan, a leading independent research and consulting firm, has
awarded IQVIA with the 2024 Global Customer Value Leadership Award
for excellence in the global artificial intelligence (AI) quality
and regulatory solutions space for the healthcare industry.
Frost & Sullivan’s annual Customer Value Leadership Award
recognizes the company that offers products or services that
customers find superior in overall price, performance and quality.
IQVIA was awarded this recognition for its Enterprise Quality
Management System (eQMS), SmartSolve®, which serves as a single
source of truth ecosystem that simplifies the complexity of quality
and regulatory compliance.
SmartSolve is an intelligence-driven platform that enables
quality assurance and regulatory affairs professionals to improve
patient safety, enhance product quality, drive commercial
efficiency, process effectiveness and maintain compliance. Similar
to all IQVIA AI-powered solutions, IQVIA’s SmartSolve’s eQMS
platform is grounded in IQVIA Healthcare-grade AI™, AI engineered
to meet the level of precision, speed and trust required for life
sciences and healthcare.
“It is an honor to be recognized for our transformative
artificial intelligence efforts in the quality and regulatory
space,” said Susan Hill, vice president of Global Product
Management, Digital Products & Solutions, at IQVIA. “IQVIA
empowers industry professionals with a leading Enterprise Quality
Management solution that accelerates the provision of safe and
effective care globally. This award is a testament to our focus on
driving innovation and simplifying complex processes for our
customers.”
“IQVIA’s differentiated strategy combines intelligence-driven
simplification, integration and automation to transform quality
operations and drive efficiency for QA/RA professionals,” said
Sankara Narayanan, industry director at Frost & Sullivan. “With
tailored, customer-centric solutions that leverage AI to streamline
workflows, provide insights into individual activities and drive
operational improvements, IQVIA prioritizes patient safety and
enhances commercial performance.”
Discover how SmartSolve can enhance your quality management
processes by visiting our website. Read Frost & Sullivan’s full
report here to learn more about IQVIA’s recognition and the
benefits of the SmartSolve platform.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical
research services, commercial insights and healthcare intelligence
to the life sciences and healthcare industries. IQVIA’s portfolio
of solutions are powered by IQVIA Connected Intelligence™ to
deliver actionable insights and services built on high-quality
health data, Healthcare-grade AI™, advanced analytics, the latest
technologies and extensive domain expertise. With approximately
88,000 employees in over 100 countries, including experts in
healthcare, life sciences, data science, technology and operational
excellence, IQVIA is dedicated to accelerating the development and
commercialization of innovative medical treatments to help improve
patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240919580830/en/
Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.973.541.3558
Trent Brown, IQVIA Media Relations (trent.brown@iqvia.com)
+1.919.780.3221
IQVIA (NYSE:IQV)
Historical Stock Chart
From Oct 2024 to Nov 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Nov 2023 to Nov 2024